Recent Updates
Recently added Catalysts

apomorphine infusion

Phase 3

Idiopathic Parkinson's Disease | Small molecule | Neurology |Supernus Pharmaceuticals, Inc.|Last Updated: Jun 19, 2025

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
UNCONTROLLEDBiomarker
Total Trials1
Total Enrollment99
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02339064Infusion of Apomorphine: Long-term Safety StudyPHASE3 ACTIVE NOT_RECRUITING 99 — — Feb 1, 2015Dec 1, 2025Jun 19, 202518 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Percent of daily "off" time during the waking day
Baseline Visit to Week 12
Secondary Endpoints
Percent daily "on" time without troublesome dyskinesias during waking day
Baseline Visit to Week 12
Percent of daily "off" time during the waking day
Baseline Visit to Treatment Weeks 2, 4, 8, 20, 28, 36, 44, and 52; and all Treatment Extension Period Visits
Percent of daily "on" time without troublesome dyskinesias during the waking day
Baseline Visit to Treatment Weeks 2, 4, 8, 20, 28, 36, 44, and 52; and all Treatment Extension Period Visits
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Apomorphine infusionEXPERIMENTALContinuous subcutaneous apomorphine infusion
Interventions
NameTypeDescription
apomorphine infusionDRUGTreatment with apomorphine provided by continuous subcutaneous infusion using a portable external electronic pump device
Unlock Study Design Details
Eligibility Criteria
Age Range30 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites18

Inclusion Criteria: * Advanced idiopathic PD consistent with UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria * Overall motor control is unsatisfactory in the opinion of the Investigator and subject despite optimized treatment with available therapies, which must include a sta...

Countries:United States
Unlock Eligibility Criteria
Recent Changes (Last 90 Days)
LOWMay 24, 2026NCT02339064studyFirstPostDate: changed